May 13th 2025
According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
AAPS PharmSci 360: LBFs and Tackling Oral Biologic Formulations
October 22nd 2024At AAPS PharmSci 360, Karunakar Sukuru, RPh, PhD, the global vice-president-Rx Product Development, Pharma and Consumer Health, at Catalent Pharma Solutions, discussed lipid-based formulations and tackling bioavailability challenges for oral biologics.
CPHI Milan 2024: Heparin and Heparinoids in Pharmaceuticals
October 10th 2024Pharmaceutical Technology Europe sat down with Joan Bassa, Human Health Business Unit Director at Bioiberica, to talk about the history of heparin, its uses in pharmaceuticals, and what heparinoids have to offer the industry.
AAPS PharmSci 360 2024: Predictive Models for Poorly Soluble Drugs
October 10th 2024Pharmaceutical Technology sat down with Niloufar Salehi, advisor at Eli Lilly & Company, to talk about the session she is moderating at AAPS PharmSci 360 2024, Symposium: An Accelerated Development of Poorly Soluble Drugs Using Predictive Tool.
Drug Digest: Securing the Supply Chain for Small-Molecule APIs and Excipients
October 4th 2024In this exclusive Drug Digest video interview, Felicity Thomas, Associate Editorial Director, Pharmaceutical Technology Group, interviews experts about key trends impacting small-molecule APIs and excipients, the importance of supply chain resilience, ways in which advanced manufacturing approaches can prove beneficial, and potential hurdles facing companies seeking to secure their small-molecule API and excipient supply chains.
AAPS PharmSci 360 2024: Drug Delivery in Early Development
October 3rd 2024Pharmaceutical Technology sat down with Erica Schlesinger, vice president of technical development at Serán Bioscience, to talk about her upcoming presentation at AAPS PharmSci 360 2024, “High Dose Subcutaneous Delivery of Protein Therapeutics.”